Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

Pfiz­er has laid out the de­tailed re­sults be­hind its boast that etrasi­mod — the S1P re­cep­tor mod­u­la­tor at the cen­ter of its $6.7 bil­lion buy­out of Are­na Phar­ma — is the win­ner of the class, po­ten­tial­ly leapfrog­ging an ear­li­er en­trant from Bris­tol My­ers Squibb.

Piv­otal da­ta from the EL­E­VATE pro­gram in ul­cer­a­tive col­i­tis — which con­sists of two Phase III tri­als, one last­ing 52 weeks and the oth­er just 12 weeks — il­lus­trate an “en­cour­ag­ing bal­ance of ef­fi­ca­cy and safe­ty,” ac­cord­ing to Michael Cor­bo, chief de­vel­op­ment of­fi­cer of in­flam­ma­tion & im­munol­o­gy at Pfiz­er. The com­pa­ny is pre­sent­ing the re­sults as a late break­er at Di­ges­tive Dis­ease Week.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN